From: Assessment of lipophilicity of newly synthesized celecoxib analogues using reversed-phase HPLC
Compound | log k = log kw − S\(\varphi\) | |||||||||
---|---|---|---|---|---|---|---|---|---|---|
Log kw | SDa | S | SDb | r | R2 | Syx | F | \(\varphi\) 0 | Range | |
11a | 2.593 | ± 0.331 | − 0.040 | ± 0.005 | 0.9804 | 0.9610 | 0.074 | 74.10 | 64.83 | 60–80 |
11b | 3.597 | ± 0.826 | − 0.052 | ± 0.012 | 0.9301 | 0.8650 | 0.186 | 19.25 | 69.81 | 60–80 |
11c | 3.151 | ± 0.359 | − 0.042 | ± 0.005 | 0.9785 | 0.9570 | 0.081 | 67.59 | 75.14 | 60–80 |
11d | 4.784 | ± 0.887 | − 0.061 | ± 0.012 | 0.9627 | 0.9270 | 0.136 | 25.30 | 77.99 | 65–80 |
16a | 1.941 | ± 0.413 | − 0.030 | ± 0.006 | 0.9475 | 0.8980 | 0.092 | 26.34 | 64.39 | 60–80 |
16b | 2.715 | ± 0.442 | − 0.037 | ± 0.006 | 0.9602 | 0.9220 | 0.099 | 35.47 | 72.57 | 60–80 |
17a | 4.590 | ± 1.091 | − 0.059 | ± 0.015 | 0.9098 | 0.8280 | 0.245 | 14.41 | 77.97 | 60–80 |
17b | 5.182 | ± 1.017 | − 0.069 | ± 0.014 | 0.9409 | 0.8850 | 0.229 | 23.14 | 74.52 | 60–80 |
Celecoxib | 4.180 | ± 0.445 | − 0.048 | ± 0.006 | 0.9847 | 0.9696 | 0.068 | 63.81 | 85.51 | 65–80 |